Next Phase Newsletter

A new venture fund is an impact investor focused on pediatric indications. Within this area, the firm is willing to invest in companies in therapeutics, diagnostics, medical devices or digital health that help improve pediatric care. As an impact fund, the firm donates 10% of the General Partner’s Carry Interest to fund pediatric research. The firm generally makes initial investments of $3-5M and will invest globally. The firm looks to invest in 12-15 companies out of their first fund.

Within pediatric indications, the firm is interested in Oncology, Infectious Diseases and select Rare/Orphan indications. The firm will consider any technology that helps move care forward in these areas, either directly, as a therapeutic or other treatment device or diagnostic, or indirectly, as a digital health technology that helps support care or complements treatment. For therapeutics, the firm will invest in companies that are 12-18 months from IND. For diagnostics and medical devices, the firm would like to see a proof of concept or prototype. For digital health, some post pilot sales or evidence of market traction is preferred, as is a partnership with a strategic partner, with validation of the technology.

The firm can lead or co-invest, and looks to be a board observer for every portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm headquartered in USA currently manages 3 funds, and also has an advisory business that is solely dedicated for companies trying to enter the Asian market. The firm has a focus on early-stage investments (pre-Series A to Series B) and has portfolio companies spread over the USA. The firm’s initial investment size varies, but typically falls under the $250K – 2.5M range and is dedicated to follow-on financings of existing portfolio companies. The firm invests only in USA and Canada.

Within life sciences/healthcare, the firm is most interested in medical devices and smart manufacturing in life sciences, and is much more selective when it comes to biotech or therapeutics investments. Most importantly, the firm is focused on assessing the company’s patent status and the degree of novelty. While the firm is agnostic to stage of development, ideally the companies should have a working prototype and significant key data that validates the high potential of their technology. In terms of different types of technologies or diseases areas/indications, the firm is opportunistic.

The firm has no specific management team requirements, but considers patent strategy key in reviewing potential investments. Companies should have key patents issued or a clear strategy on improving their IP portfolio. The firm has great expertise in helping USA/Canada-based companies enter Asian markets (i.e. greater China) and extend their IP coverage. The firm can act as either lead or co-investor and will seek a board seat if they come in as a lead investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in Canada is looking to participate in the Seed to Series B financings of early-stage companies with typical investments between USD 0.5 million and USD 5 million. The firm is currently operating out of its second fund in which it has made three investments after making thirteen investments out of its inaugural fund. The firm participates in equity investments including SAFEs and convertible notes. The firm invests primarily in companies based in Canada, the United States, Europe, and Israel.

The firm is primarily interested in investing in companies in the digital health sector but will also consider the medical and diagnostic devices sectors that have a digital component to them. The firm is open to all modalities within the digital health but requires that the technologies be patient facing or have a patient component. The firm will not consider investments in biotech or pharma but will consider digital therapeutics. The firm is phase agnostic and will invest in development as well as on the market technologies. The firm will only invest in Class I and Class II (510k) medical devices, avoiding Class III (PMA). The firm is disease agnostic and will consider companies across all indications but prefers that there is ample market size for the technology to be revenue generating.

The firm prefers to work with experienced management teams. The firm looks to invest in companies in which the founder has a significant stake in the business. The firm is an active and strategic investor and will take a board seat as determined by check size on a case-by-case basis. The firm will participate both as a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital investment firm founded in 2020 by experienced investment professionals and headquartered in the USA is currently operating out of its inaugural fund and is actively looking for deal flow. Typical investment size ranges from USD 0.5 million to USD 2 million. Investment strategy at the firm is evolving but currently the firm participates in equity investments only. The firm looks to partner with early-stage companies and is open to global opportunities but will typically focus on opportunities in the United States.

The firm is interested in investing in therapeutics companies, or companies in other sectors that have a therapeutic component. Within therapeutics the firm will consider assets from pre-clinical to pre-IND filing and generally prefers to see some type of proof-of-concept data. Within medical devices and diagnostics, the firm invests in technologies that are pre-commercial and is open to all classes of medical devices including Class II (510k) and Class III (PMA). The firm is disease agnostic and will invest in companies throughout all indications including those in orphan diseases.

The firm is open to working with experienced management teams. The firm looks to work with management teams that are ambitious and able to work together and execute well. The firm takes an active role in the companies in which it invests; however, the firm currently only looks to co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private investment firm launched a healthtech-focused fund to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The firm focuses on early-stage digital health projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine).

The firm is an active and engaged investor, and can act as either a lead or co-investor. The firm prefers to lead investments in seed rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A firm based in the USA and investing out of their third fund currently makes equity investments in commercial stage (post regulatory approval) healthcare companies with meaningful revenue and traction. The firm typically invests between $15-$50m per company.

The firm invests exclusively in healthcare and is open to all sub-sectors within the industry. That said, the firm does not invest in pre-revenue companies or those with regulatory risk; investments are made in revenue-generating companies with products that have already received regulatory approval or which do not require regulatory approval. The firm looks for companies with meaningful marketplace validation and growing revenues, where the firm’s investment could help to accelerate the adoption.

The firm prefers to invest in management teams with experience in leading and growing businesses of scale and relevant industry experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A listed pharmaceutical company with $5 Billion of assets under management has become a high-tech pharmaceutical health industry cluster that covers manufacturing, R&D, and sales in the pharmaceutical area after 2 decades of arduous efforts. The firm is open to global R&D partnerships and investment opportunities.

The firm has a focused interest in finished drugs, pharmaceutic adjuvants, active pharmaceutical ingredients, medical devices, medical and health management services. In addition, the firm pays special attention to novel therapeutic innovations in sepsis, anti-infection, and oncology area.

The firm has no specific company or management team requirements.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.